Poxel SA (POXEL) AI Stock Analysis

• Market Cap: €12.95M
• Dividend Yield: N/A
• Average Volume (3M): 288.32K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.40
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: FR
• Employees: 6
• Sector: General
• Sector Strength: N/A
• Industry: Biotechnology
• EPS (TTM): -0.05
• Shares Outstanding: 53,758,167
• 10 Day Avg. Volume: 262,495
• 30 Day Avg. Volume: 288,318
• PEG Ratio: 0.00
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 41 Neutral
• Price Target: €0.22 ▼(-4.35% Downside)

The score is primarily weighed down by weak financial performance, driven by persistent losses, negative operating cash flow, and a highly stressed balance sheet with negative equity and rising debt. Technicals add additional pressure with a clear downtrend and negative momentum. Valuation provides limited support because the company is loss-making and no dividend yield is available.

Poxel SA Business Overview & Revenue Model

Company Description

Poxel S.A., a clinical-stage biopharmaceutical company, develops novel treatments for metabolic diseases, type 2 diabetes, and liver diseases. The company's lead product is Imeglimin, an oral drug candidate, which completed Phase III clinical development stage in Japan, as well as in Phase III in the United States and Europe for the treatment of type 2 diabetes that improves pancreatic beta cell function, reduces insulin resistance, and decreases cardiovascular and metabolic disease risk factors, such as heightened blood lipid levels and excess body weight. It also develops PXL770, an adenosine monophosphate-activated protein kinase enzyme, which is in a Phase 2a clinical trial that treats chronic metabolic diseases, including diseases that affect the liver, such as non-alcoholic steatohepatitis (NASH). The company has a licensing agreement with Enyo Pharma S.A.S. for the development of PXL007 (EYP001), a synthetic non-steroidal and non-bile acid FXR agonist that is in Phase II study for the treatment of hepatitis B and NASH; and DeuteRx LLC for the development of PXL065, a mitochondrial pyruvate carrier inhibitor, which is in a phase I clinical trial for the treatment of NASH. Poxel S.A. was incorporated in 2009 and is headquartered in Lyon, France.

How the Company Makes Money

Poxel SA Financial Statement Overview

Summary

Income Statement

Balance Sheet

Cash Flow

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	6.64M	1.98M	674.00K	13.40M	6.81M
Gross Profit	3.66M	1.00K	2.00K	13.34M	6.81M
EBITDA	-4.32M	-12.17M	-28.02M	-22.52M	-29.71M
Net Income	-18.30M	-35.09M	-31.40M	-23.76M	-31.86M
Balance Sheet
Total Assets	14.93M	4.82M	34.71M	54.89M	65.08M
Cash, Cash Equivalents and Short-Term Investments	3.66M	2.34M	13.06M	32.29M	40.20M
Total Debt	69.71M	47.03M	43.44M	35.14M	23.62M
Total Liabilities	73.87M	53.90M	52.95M	46.68M	38.20M
Stockholders Equity	-58.94M	-49.10M	-18.24M	8.21M	27.07M
Cash Flow
Free Cash Flow	0.00	3.05M	-21.84M	-16.94M	-26.03M
Operating Cash Flow	-17.61M	-13.98M	-21.81M	-16.89M	-25.75M
Investing Cash Flow	92.00K	41.00K	-5.00K	-42.00K	52.00K
Financing Cash Flow	18.82M	3.23M	2.58M	9.03M	28.71M

Poxel SA Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	55 Neutral	$6.65B	3.83	-15.92%	6.20%	10.91%	7.18%
ALDVI	49 Neutral	€24.63M	-3.53	―	―	101.95%	35.55%
ALVAL	49 Neutral	€16.58M	-1.16	―	―	―	―
ALTHX	45 Neutral	€26.35M	-5.54	―	―	―	10.30%
ABNX	44 Neutral	€131.05M	-28.05	-62.40%	―	-10.91%	-25.57%
POXEL	41 Neutral	€12.95M	-0.91	―	―	―	―